WILEX Inc., a subsidiary of WILEX AG, is an established leader focused on delivering companion diagnostics for targeted oncology therapies. Our well-reputed Oncogene Science biomarker tests continue to provide clinical researchers the tools they need for advancing oncology research as well as to assist in drug discovery and development.

 

Along with our selection of research use only kits, we strive to provide the medical community reliable in vitro diagnostics, such as our Serum HER-2/neu ELISA test, for the monitoring and management of patient care. Please visit our Products page to learn about our high quality tests for measuring oncogenes, growth factor receptors (HER-2, EGFr), proteases and protease inhibitors (uPA, PAI-1, TIMP-1), as well as markers of hypoxia (CA IX).

Latest News: WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics

Learn more about WILEX AG

 

read: 1 | today: 1